Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK.

Varda-Bloom N, Hodish I, Shaish A, Greenberger S, Tal R, Feder B, Roitelman J, Breitbart E, Bangio L, Barshack I, Pfeffer R, Harats D.

Pathobiology. 2008;75(6):346-55. doi: 10.1159/000164219.

PMID:
19096230
2.

Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK.

Hodish I, Tal R, Shaish A, Varda-Bloom N, Greenberger S, Rauchwerger A, Breitbart E, Bangio L, Ben-Shushan D, Pfeffer R, Feder B, Waitsman A, Barshack I, Goldberg I, Mazaki-Tovi S, Peled M, Harats D.

Cancer Biol Ther. 2009 Mar;8(5):424-32.

PMID:
19276657
3.

Tissue-specific gene therapy directed to tumor angiogenesis.

Varda-Bloom N, Shaish A, Gonen A, Levanon K, Greenbereger S, Ferber S, Levkovitz H, Castel D, Goldberg I, Afek A, Kopolovitc Y, Harats D.

Gene Ther. 2001 Jun;8(11):819-27.

4.

Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.

Ebara S, Shimura S, Nasu Y, Kaku H, Kumon H, Yang G, Wang J, Timme TL, Aguilar-Cordova E, Thompson TC.

Prostate Cancer Prostatic Dis. 2002;5(4):316-25.

5.

Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice.

Dancer A, Julien S, Bouillot S, Pointu H, Vernet M, Huber P.

Gene Ther. 2003 Jul;10(14):1170-8.

PMID:
12833126
6.

Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer.

Park KH, Kim G, Jang SH, Kim CH, Kwon SY, Yoo CG, Kim YW, Kwon HC, Kim CM, Han SK, Shim YS, Lee CT.

Anticancer Res. 2003 Mar-Apr;23(2B):1559-64.

PMID:
12828142
7.

Tumor-specific transcriptional targeting of suicide gene therapy.

Qiao J, Doubrovin M, Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH, Woo SL.

Gene Ther. 2002 Feb;9(3):168-75.

8.

Effectiveness of HSV-tk suicide gene therapy driven by the Grp78 stress-inducible promoter in esophagogastric junction and gastric adenocarcinomas.

Azatian A, Yu H, Dai W, Schneiders FI, Botelho NK, Lord RV.

J Gastrointest Surg. 2009 Jun;13(6):1044-51. doi: 10.1007/s11605-009-0839-1.

PMID:
19277794
10.

Cytotoxicity and antiangiogenesis by fibroblast growth factor 2-targeted Ad-TK cancer gene therapy.

Saito K, Khan K, Sosnowski B, Li D, O'Malley BW Jr.

Laryngoscope. 2009 Apr;119(4):665-74. doi: 10.1002/lary.20127.

PMID:
19213040
11.

In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.

Pramudji C, Shimura S, Ebara S, Yang G, Wang J, Ren C, Yuan Y, Tahir SA, Timme TL, Thompson TC.

Clin Cancer Res. 2001 Dec;7(12):4272-9.

12.

Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.

Määttä AM, Korja S, Venhoranta H, Hakkarainen T, Pirinen E, Heikkinen S, Pellinen R, Mäkinen K, Wahlfors J.

Int J Mol Med. 2006 Nov;18(5):901-8.

PMID:
17016620
13.

Combinatory gene therapy with electrotransfer of midkine promoter-HSV-TK and interleukin-21.

Hanari N, Matsubara H, Hoshino I, Akutsu Y, Nishimori T, Murakami K, Sakata H, Miyazawa Y, Ochiai T.

Anticancer Res. 2007 Jul-Aug;27(4B):2305-10.

14.

Avian adenovirus vector CELO-TK displays anticancer activity in human cancer cells and suppresses established murine melanoma tumors.

Shashkova EV, Cherenova LV, Kazansky DB, Doronin K.

Cancer Gene Ther. 2005 Jul;12(7):617-26.

PMID:
15761475
15.

Optimization of radiation controlled gene expression by adenoviral vectors in vitro.

Anton M, Gomaa IE, von Lukowicz T, Molls M, Gansbacher B, Würschmidt F.

Cancer Gene Ther. 2005 Jul;12(7):640-6.

PMID:
15803145
16.

Transcription-controlled gene therapy against tumor angiogenesis.

Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, Barshack I, Hodish I, Yaacov N, Bangio L, Goncharov T, Wallach D, Harats D.

J Clin Invest. 2004 Apr;113(7):1017-24.

17.

Lack of enantioselectivity of herpes virus thymidine kinase allows safer imaging of gene delivery.

Magrassi L, Finocchiaro G, Milanesi G, Benvenuto F, Spadari S, Focher F.

Gene Ther. 2003 Dec;10(25):2052-8.

PMID:
14595377
18.

Antitumor effects of non-replicative herpes simplex vectors expressing antiangiogenic proteins and thymidine kinase on Lewis lung carcinoma establishment and growth.

Berto E, Bozac A, Volpi I, Lanzoni I, Vasquez F, Melara N, Manservigi R, Marconi P.

Cancer Gene Ther. 2007 Sep;14(9):791-801.

PMID:
17557110
19.

[An experimental study on targeting suicide gene therapy for lung cancer with HSV-TK driven by hTERT promoter].

Wang YP, Tang XJ, Zhou QH, Che GW, Chen XH, Zhu DX.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2008 Sep;39(5):701-5. Chinese.

PMID:
19024294
20.

Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model.

Terao S, Shirakawa T, Goda K, Kamidono S, Fujisawa M, Gotoh A.

Anticancer Res. 2005 Jul-Aug;25(4):2757-60.

Items per page

Supplemental Content

Support Center